Department of Diagnostic and Interventional Radiology, St James's University Hospital, Leeds, UK.
Leeds Institute of Medical Research, University of Leeds, Leeds, UK.
Br J Radiol. 2021 Sep 1;94(1125):20210475. doi: 10.1259/bjr.20210475. Epub 2021 Jul 28.
To determine biopsy device failures, causative factors, complications and sample quality of the 16G end-cut Biopince and side-notch Bard needles.
All ultrasound-guided non-targeted liver biopsies between 01/01/2016 and 31/12/2018 were included. Operator, device, number of failures, complications and repeat biopsies were recorded. Histopathology samples were reviewed for all cases of needle failure and a group with no failures, and graded "yes/no" for the presence of steatosis, inflammation and fibrosis. The pathology slides from these cases were reviewed to assess biopsy sample quality (length and portal tract number). The failure and no-failure groups were compared in terms of device type/histology, and sample quality was compared between the needle types.
1004 patients were included. 93.8% ( = 942) required one needle pass to obtain a sample and 6.2% ( = 62) required >1 pass due to needle failure. Total of 76 needle failures, more with end-cut than side-notch needles (8.7% 2.9%) ( < 0.001). No needle failures resulted in complication. The presence of liver fibrosis was associated with fewer needle failures ( = 0.036). The major complication rate was 0.4% (4/1044). A biopsy with >10 portal tracts was obtained in 90.2% of specimens > 20 mm long, compared with 66% of 16-20 mm biopsies and 21% of <16 mm biopsies. The target of >10 portal tracts was achieved in 10/26 (38.5%) of side-notch biopsies and 64/90 (71.1%) of end-cut biopsies ( = 0.004).
Ultrasound-guided liver biopsy is safe and sample quality is consistently good when a core >20 mm long is obtained. The end-cut biopsy device generated reliably good quality biopsy samples; however, the needle failure rate was significantly higher than the side-cut needle.
Ultrasound-guided liver biopsy specimen quality is consistently good when a core >20 mm long is obtained which can be achieved with a single pass using the 16G Biopince end-cut needle, although the needle failure rate is significantly higher than the 16G Max-Core Bard side-notch needle.
确定 16G 端切 Biopince 和侧切 Bard 针的活检装置故障、原因、并发症和样本质量。
纳入 2016 年 1 月 1 日至 2018 年 12 月 31 日期间所有超声引导下非靶向性肝活检。记录操作者、器械、故障次数、并发症和重复活检。对所有针具失败和无失败的病例进行组织病理学检查,并对存在脂肪变性、炎症和纤维化的病例进行“是/否”分级。评估这些病例的活检样本质量(长度和门管区数量),并比较针类型之间的样本质量。
纳入 1004 例患者。93.8%(=942 例)需要一次进针即可获得样本,6.2%(=62 例)因针具故障需要>1 次进针。总共发生 76 次针具故障,端切针比侧切针更常见(8.7%比 2.9%)(<0.001)。无针具故障导致并发症。存在肝纤维化与针具故障较少相关(=0.036)。主要并发症发生率为 0.4%(4/1044)。>20mm 长的活检标本中,>10 个门管区的标本占 90.2%,16-20mm 活检标本占 66%,<16mm 活检标本占 21%。26 个侧切活检中有 10 个(38.5%)和 90 个(71.1%)端切活检(=0.004)目标>10 个门管区。
超声引导下肝活检是安全的,当获得>20mm 长的核心组织时,样本质量始终良好。端切活检装置生成的活检样本质量可靠,但针具故障发生率明显高于侧切针。
当获得>20mm 长的核心组织时,超声引导下肝活检标本质量始终良好,使用 16G Biopince 端切针可一次进针完成,尽管针具故障发生率明显高于 16G Max-Core Bard 侧切针。